

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Att'y. Docket No.

04-105 (400/146)

Serial No.

10/783,128

**FIFTH SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant:

McSwiggen et al.

Filing Date:

February 20, 2004

Group:

1635

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
/K.C./	*	US-2002/0086356	03/30/01	Tuschl et al.			07/04/02
	*	US-2002/0151693	02/08/01	Breaker et al.			10/17/02
	*	US-2003/0059944	09/13/02	Lois-Caballe et al.			03/27/03
	*	US-2003/0064945	07/25/01	Akhtar et al.			04/03/03
	*	US-2003/0143732	08/30/02	Fosnaugh et al.			07/31/03
	*	US-2004/0019001	07/26/02	McSwiggen et al.			01/29/04
	*	US-2004/0161844	11/04/03	Baker et al.			08/19/04
	*	US-2005/0182005	05/13/04	Tuschl et al.			02/18/05
	*	US-2005/0227256	11/26/04	Hutvagner et al.			10/13/05

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
/K.C./	*	5,587,471	12/24/96	Cook et al.			
	*	5,998,206	12/07/99	Cowser			
	*	6,060,456	05/09/00	Arnold et al.			
	*	6,214,805	04/10/01	Torrence et al.			

EXAMINER

/Kimberly Chong/

DATE CONSIDERED

09/10/2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-105 (400/146)	Serial No. 10/783,128
		Applicant: McSwiggen et al.	
		Filing Date: February 20, 2004	Group: 1635

**FIFTH SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

/K.C./	*	6,346,398	02/12/02	Pavco et al.			
↓	*	6,573,099	06/03/03	Graham et al.			
	*	6,824,972	11/30/04	Kenwrick et al.			
	*	7,022,828	04/04/06	McSwiggen et al.			
↓	*	7,078,196	07/18/06	Tuschl et al.			

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclasses	Translation	
							Yes	No
/K.C./	1.	1389637	08/05/02	EP (Klippel et al.)				
↓	2.	03/044188	11/21/02	WO (Tei et al.)				
	3.	04/013280	02/12/04	WO (Davidson et al.)				
	4.	04/029212	04/08/04	WO (Rana, Tariq M.)				
	*	04/047872	06/10/04	WO (Kaemmerer et al.)				
	5.	04/048566	11/21/03	Saigo et al.				
	6.	04/090105	10/21/04	WO (Leake et al.)				
↓	7.	05/049821	11/18/04	WO (Naito et al.)				

EXAMINER /Kimberly Chong/	DATE CONSIDERED 09/10/2007
----------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 04-105 (400/146)	Serial No. 10/783,128
		Applicant: McSwiggen et al.	
		Filing Date: February 20, 2004	Group: 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

/K.C.	8.	Alexeev et al., "Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," <i>Nature Biotechnology</i> , 18:43-47 (2000)
	9.	Bellon et al., "4-Thio-oligo- β -D-ribonucleotides: synthesis of β -4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase," <i>Nucleic Acids Research</i> , 21(7):1587-1593 (1993)
	10.	Bernstein et al., "The rest is silence," <i>RNA</i> , 7:1509-1521 (2001)
	11.	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiology</i> , 1:34 (11 pgs) (2001)
	12.	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
	13.	Braasch et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)
	14.	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," <i>Science</i> , 309, 1529-1530 (2005)
	15.	Czech, Michael P., "MicroRNAs as Therapeutic Targets," <i>The New England Journal of Medicine</i> , 354, 1194-1195 (2006)
	16.	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213 (2002)
	17.	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> , 543:51-54 (2003)
	18.	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
	19.	Hornung et al., "Sequence-specific potent induction of IFN- α by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)
↓	20.	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <i>Nature Biotechnology</i> , 23(4):457-462 (2005)

EXAMINER /Kimberly Chong/	DATE CONSIDERED 09/10/2007
----------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 04-105 (400/146)	Serial No. 10/783,128
	Applicant: McSwiggen et al.	
	Filing Date: February 20, 2004	Group: 1635

/K.C./	21. Kawaski et al., "Uniformly Modified 2'-Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," <i>J. Med. Chem.</i> , 36, 831-841 (1993)
	22. Mahato et al., "Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA," <i>Expert Opinion</i> , 2(1):3-28 (2005)
	23. Mattick, John S., "The Functional Genomics of Noncoding RNA", <i>Science</i> , 309, 1527-1528 (2005)
	24. McCaffrey et al., "RNA interference in adult mice," <i>Nature</i> , 148, 38-39 (2002)
	25. Miller et al., "Allele-specific silencing of dominant disease genes," <i>PNAS</i> , 100:12, 7195-7200 (2003)
	26. Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <i>J. Biol. Chem.</i> 268:14514-14522 (1993)
	27. Morvan et al., "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," <i>J. Med. Chem.</i> , 36, 280-287 (1993)
	28. Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," <i>Biochimica et Biophysica Acta</i> , 1576, 101-109 (2002)
	29. Opalinska et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Reviews Drug Discovery</i> , (1):503-514 (2002)
	30. Scherer et al., "Approaches for the sequence-specific knockdown of mRNA," <i>Nature Biotech.</i> , 21(12):1457-1465 (2003)
	31. Sethupathy et al., "TarBase: A comprehensive database of experimentally supported animal microRNA targets," <i>RNA</i> , 12:192-197 (2006)
	32. Xia et al., "RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia," <i>Nature Medicine</i> , 10(8):816-820 (2004)
↓	33. Zhang et al., "Single Processing Center Models for Human Dicer and Bacterial RNase III," <i>Cell</i> , 118:57-68 (2004)

EXAMINER /Kimberly Chong/	DATE CONSIDERED 09/10/2007
----------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32) FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 04-105 (400/146)	Serial No. 10/783,128
			Applicant: McSwiggen et al.	
			Filing Date: February 20, 2004	Group: 1635

/K.C./ 34.	Zhang et al., "Targeted Gene Silencing by Small Interfering RNA-Based Knock-Down Technology," <i>Current Pharmaceutical Biotechnology</i> , 5:1-7 (2004)
------------	--

EXAMINER /Kimberly Chong/	DATE CONSIDERED 09/10/2007
----------------------------------	-----------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.